204 results
Page 2 of 11
6-K
EX-99.1
cwdtidq 91ssfn
22 Aug 22
Bellus Health Inc. 6-K
7:01am
6-K
EX-99.1
g3h4angkr00i3a5vjm2
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
6-K
EX-99.2
jnoma5ih9m68az
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
6-K
EX-99.1
ba2jra 74q3uo4u9
10 Aug 22
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
4:31pm
6-K
EX-99.1
0xo62b5gw 4q
18 Jul 22
BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States
4:05pm
SUPPL
y5c0kdqrwumpbfhyv
15 Jul 22
Supplemental materials (foreign)
7:01am
6-K
EX-99.1
d1d0h5fnfpig7 99jpq
14 Jul 22
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
4:46pm
SUPPL
2g4s7uh7agcin
13 Jul 22
Supplemental materials (foreign)
5:01pm
6-K
EX-99.2
g3j5lmgtfoiggyy
13 Jul 22
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
4:25pm
6-K
EX-99.1
rgnby mthq03w7e
13 Jul 22
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
4:25pm
6-K
EX-99.1
c9c2ce
12 Jul 22
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
7:27am
6-K
s6wnijnmub7cse1
12 Jul 22
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
7:27am
6-K
EX-99.2
qvp jfmg8weux0a
12 Jul 22
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
7:27am
6-K
EX-99.1
z6mzvfnlet 8rm2ds9d
5 Jul 22
BELLUS Health to Participate in the William Blair Biotech Focus Conference
7:00am
6-K
EX-99.1
8fqaw5
1 Jun 22
BELLUS Health to Participate in the Jefferies Healthcare Conference
7:00am
6-K
EX-99.1
6mhrv
11 May 22
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
5:23pm
6-K
EX-99.2
mncvfde9
11 May 22
Condensed Consolidated Interim Financial Statements of
5:05pm
6-K
EX-99.1
j5qlgyoau12mj6y
11 May 22
Condensed Consolidated Interim Financial Statements of
5:05pm
6-K
EX-99.1
lw8fogqje
2 May 22
BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference
7:00am
6-K
EX-99.1
c5bq3rtampdyrmg
25 Apr 22
BELLUS Health to Participate in Multiple Upcoming Investor Conferences
4:02pm